Moreover, Taz treatment could upregulate Treg recruitment in tumor‐draining lymph nodes (tDLNs), reducing the CD8+/Treg ratio and thereby skewing the immune environment toward immunosuppression. This evidence concerns the gene CD8A and neoplasm.